GlobeNewswire EN Nachrichten

 

Majority ownership of Vireo Health of New York to transfer to MWBE-led Ace Ventures; partnership reinforces long-term alignment with New York's social equity framework Majority ownership of Vireo Health of New York to transfer to MWBE-led Ace Ventures; partnership reinforces long-term alignment with New York's social equity framework...

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity of at least $6.0 million if it has ...

BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation....

LAS VEGAS, NEVADA., April 03, 2026 (GLOBE NEWSWIRE) -- Jena Acquisition Corporation II (the “Company”) announced today that on April 1, 2026, the Company received a written notice from the staff of NYSE Regulation of the New York Stock Exchange (“NYSE”) indicating that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual (the “Listing Rule”) which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis....

HONG KONG, April 03, 2026 (GLOBE NEWSWIRE) -- AIOS Tech Inc. (NASDAQ: AIOS) (the “Company”), today announced that, on April 1, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the Class A Common Shares of the Company for the last 30 consecutive business days, the Company no longer meets the continued listing requirements of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share....

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan....

EFFINGHAM, Ill., April 03, 2026 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) announced today that it will issue its first quarter 2026 financial results after market close on Thursday, April 23, 2026. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the Webcasts and Presentations page of its investor relations website....

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2026 (the “Grant Date”), ORIC granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026....

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711...

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards...

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment....

HONOLULU, April 03, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its first quarter 2026 financial results on Friday, April 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company's results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time)....

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates....

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on April 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)....

The artisan-crafted furnishings brand deepens its roots in Northern Virginia with a new showroom opening at One Loudoun...

PENNSAUKEN, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty healthcare, and information technology services, today announced financial results for the fourteen and fifty-three weeks ended January 3, 2026....

DBM Global Inc. declares cash dividend...

Office of the CEO Established to Oversee Business Operations ...

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company's common stock to five newly-hired non-executive employees under the Company's 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company's common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installme...